Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas

Pearl, Michael L.; Inagami, M.; McCauley, Dayna L.; Valea, Fidel A.; Chalas, Eva; Fischer, Margaret

doi:10.1046/j.1525-1438.2002.01139.x

Cited by 13 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[28][29][30][31] Results of both in vitro and in vivo studies suggest that DTIC acts synergistically with anthracyclines and has a moderate effect in the treatment of high-grade sarcomas in humans. [32][33][34][35][36] Vincristine has demonstrated modest responses in a limited number of canine HSA patients. 25,37 The authors hypothesized that the DAV combination would be effective in providing clinical responses in dogs with advanced-stage noncutaneous HSA.…”

Section: Introductionmentioning

confidence: 99%

Treatment with DAV for Advanced-Stage Hemangiosarcoma in Dogs

Dervisis

Domı́nguez

Newman

et al. 2011

Journal of the American Animal Hospital Association

View full text Add to dashboard Cite

Hemangiosarcoma (HSA) is an aggressive disease that is fairly common in the dog. The authors evaluated a doxorubicin, dacarbazine, and vincristine (DAV) combination protocol in dogs with nonresectable stage II and stage III HSA. Twenty-four dogs were enrolled in this prospective, phase 2 study. Doxorubicin and dacarbazine were administered on day 1 while vincristine was administered on days 8 and 15. The protocol was repeated every 21 days for a maximum of six cycles or until disease progression. Toxicity and efficacy were assessed by clinical and laboratory evaluation and by questionnaires completed by the owners. Of the 24 included dogs, 19 were evaluable for response. The response rate (including five complete responses and four partial responses) was 47.4%. Median time to tumor progression was 101 days and median overall survival was 125 days.Significant toxicities were noted, including 41 high-grade hematologic and 12 high-grade gastrointestinal toxic events.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment with DAV for Advanced-Stage Hemangiosarcoma in Dogs

Dervisis

Domı́nguez

Newman

et al. 2011

Journal of the American Animal Hospital Association

View full text Add to dashboard Cite

show abstract

“…The chemo-therapeutic regimen for uterine carcinosarcomas includes the same drugs also used for uterine malignant stromal tumors such as leiomyosarcomas or undifferentiated sarcomas [5]. However, the chemotherapies currently proposed are inadequate to control metastatic and unresectable diseases [6].…”

Section: Introductionmentioning

confidence: 99%

COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?

Raspollini

Susini

Amunni

et al. 2005

Gynecologic Oncology

View full text Add to dashboard Cite

Objectives. Uterine carcinosarcomas are uncommon, highly aggressive neoplasms that frequently recur after surgical treatment and adjuvant chemo-radiotherapy. Patients with recurrent disease respond poorly to salvage chemotherapy and irradiation. New therapeutic options are required for patients with metastatic disease. Clinical evidences showing the effect of a tyrosine kinase inhibitor, STI571, in c-KIT-positive gastrointestinal tumors, the role of COX-inhibitors chemotherapy-associated in colorectal cancer patients and the successful therapeutic possibility of anti-HER2 therapy in metastatic breast carcinoma, have encouraged us to study the expression of c-KIT, COX-2 and HER-2/neu in uterine carcinosarcomas.Methods. We analyzed the expression of COX-2, c-KIT and HER-2/neu in 24 uterine carcinosarcomas and their correlation with clinical outcome. Disease-free interval and actuarial survival rates were the end points of the study.Results. High staining intensity for COX-2 was observed in 8 cases (33.3%). C-KIT was expressed in 4 cases (16.7%) and HER-2/neu in 7 cases (29.2%). Patients with COX-2-positive tumors had a significantly poorer disease-free interval and survival ( P = 0.01 and P = 0.05, respectively). All patients with c-KIT-positive tumors had early stage disease. In spite of this, their survival was not significantly better than that of c-KIT-negative cases. HER-2/neu expression did not show any correlation with clinical outcome.Conclusion. c-KIT, COX-2, and HER-2/neu were expressed in different proportions of uterine carcinosarcomas. COX-2 expression was a strong indicator of unfavorable prognosis. These results warrant further study to evaluate the possible role of a new molecularly targeted cancer therapy with COX-2 inhibitors in patients with uterine carcinosarcomas. The role of c-KIT expression and consequently the hypothetical use of STI571 should be tested in a larger series.

show abstract

“…Pearl et al (18) investigated MAID therapy in 23 patients with gynecological sarcoma, including uterine LMS and adenosarcoma. The overall response rate was 33.3% and the disease control rate was 50.0%.…”

Section: Discussionmentioning

confidence: 99%

A retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for progressive or recurrent uterine sarcoma

Yamagami

Susumu

Ninomiya

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. There is currently insufficient evidence to recommend a specific chemotherapeutic regimen as standard treatment for uterine sarcomas. In this study, we investigated the toxicity and effectiveness of ifosfamide, adriamycin and cisplatin (IAP therapy) in patients with progressive and recurrent uterine sarcoma. A total of 11 patients with progressive or recurrent uterine sarcoma containing leiomyosarcoma (LMS), undifferentiated endometrial sarcoma (UES) or adenosarcoma, who were diagnosed at our institution, were retrospectively investigated. We recorded the adverse events, response rate and progression-free survival in these cases. The histological types included LMS (54.5%), adenosarcoma (27.3%) and UES (18.2%). Grade ≥3 leukopenia or neutropenia were observed in all the cases, febrile neutropenia developed in 45.5% of the patients and grade 4 thrombocytopenia developed in 3 cases (27.3%). With IAP therapy, the response rate was 36.4% and the disease control rate was 90.9%. Therefore, IAP therapy may be a viable option as chemotherapy for uterine sarcoma.

show abstract

Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas

Cited by 13 publications

References 5 publications

Treatment with DAV for Advanced-Stage Hemangiosarcoma in Dogs

Treatment with DAV for Advanced-Stage Hemangiosarcoma in Dogs

COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?

A retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for progressive or recurrent uterine sarcoma

Contact Info

Product

Resources

About